* Regeneron And Sanofi announce positive Dupilumab topline results from two Phase 3 trials in inadequately controlled moderate to-severe atopic Dermatitis patients
The post BRIEF-Regeneron and Sanofi announce positive Dupilumab topline results from two Phase 3 trials in inadequately controlled moderate-to-severe atopic Dermatitis patients appeared first on NASDAQ.